Development of ICT01, a First-in-Class, Anti-BTN3A Antibody for Activating Vγ9Vδ2 T Cell–Mediated Antitumor Immune Response

The authors described the development of a humanized monoclonal antibody, ICT01, with subnanomolar affinity for the three isoforms of BTN3A.